-
公开(公告)号：WO2008036967A2
公开(公告)日：2008-03-27
申请号：PCT/US2007079286
申请日：2007-09-24
Applicant: REDDY US THERAPEUTICS INC , REDDY DUMBALA SRINIVAS , PADMALAYAM INDIRA , BHUNIYA DEBNATH , PILLARISETTI SIVARAM , CHAKRABARTI RANJAN
Inventor： REDDY DUMBALA SRINIVAS , PADMALAYAM INDIRA , BHUNIYA DEBNATH , PILLARISETTI SIVARAM , CHAKRABARTI RANJAN
IPC: A61K31/405
CPC classification number: C07D209/12 , C07D209/18 , C07D401/06
Abstract: This invention provides a compound of formula (I), which is a free species and/or a pharmaceutically-acceptable salt or a stereoisomer of the compound of formula (I). Another aspect of the present invention provides the compound of the formula (I) as a Lipoic acid synthase (LASY) inducer
Abstract translation: 本发明提供式（I）化合物，其是式（I）化合物的游离物质和/或药学上可接受的盐或立体异构体。 本发明的另一方面提供了作为硫辛酸合酶（LASY）诱导剂的式（I）化合物
-
公开(公告)号：WO2011048148A3
公开(公告)日：2011-06-30
申请号：PCT/EP2010065802
申请日：2010-10-20
Applicant: NOVARTIS AG , BEBERNITZ GREGORY RAYMOND , BOCK MARK G , BHUNIYA DEBNATH , DATRANGE LAXMIKANT , KURHADE SURESH EKNATH , PALLE P VENKATA , REDDY DUMBALA SRINIVAS
Inventor： BEBERNITZ GREGORY RAYMOND , BOCK MARK G , BHUNIYA DEBNATH , DATRANGE LAXMIKANT , KURHADE SURESH EKNATH , PALLE P VENKATA , REDDY DUMBALA SRINIVAS
IPC: C07H15/203 , A61K31/351 , A61K31/7034 , A61K31/7042 , A61K31/7056 , A61P3/10 , C07D309/10 , C07D309/30 , C07D405/10 , C07D407/10 , C07D407/12 , C07D409/04 , C07D409/10 , C07D409/12 , C07D413/10 , C07D491/107 , C07D493/10 , C07D498/04 , C07H15/26 , C07H17/00 , C07H19/04
CPC classification number: C07H17/00 , A61K31/351 , A61K31/7034 , A61K31/7042 , A61K31/7056 , A61K38/28 , A61K45/06 , C07D309/10 , C07D309/30 , C07D405/10 , C07D407/10 , C07D407/12 , C07D409/04 , C07D409/10 , C07D409/12 , C07D413/10 , C07D491/107 , C07D493/10 , C07D498/04 , C07H15/203 , C07H15/26 , C07H19/04 , A61K2300/00
Abstract: This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
Abstract translation: 本发明涉及由式（I）表示的化合物，其中变量如上文所定义，其可用于治疗由D-葡萄糖共转运蛋白钠（SGLT）介导的疾病和病症，例如， 糖尿病。 本发明还提供了治疗这些疾病和病症的方法，以及用于治疗的组合物等。
-
3.发明申请METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION, OBESITY AND RELATED METABOLIC DISORDERS 审中-公开治疗炎症，肥胖和相关代谢疾病的方法和组合物
公开(公告)号：WO2008036966A3
公开(公告)日：2008-11-06
申请号：PCT/US2007079284
申请日：2007-09-24
Applicant: REDDY US THERAPEUTICS INC , PADMALAYAM INDIRA , BHUNIYA DEBNATH , REDDY DUMBALA SRINIVAS , KHANNA ISH K , SAXENA UDAY , PILLARISETTI SIVARAM
Inventor： PADMALAYAM INDIRA , BHUNIYA DEBNATH , REDDY DUMBALA SRINIVAS , KHANNA ISH K , SAXENA UDAY , PILLARISETTI SIVARAM
IPC: A61K31/00 , A61K31/405
CPC classification number: A61K31/385 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158
Abstract: This invention provides a method of reducing inflammation in a living cell of a subject. This method increases the level of lipoic acid synthase within the living cell thereby causing the reduction of the inflammation. Various embodiments and variants are contemplated, some of which are set forth in claim format at the end of this document. The aspects, embodiments, and variants so exemplified in the claims format should not be understood as limiting the invention.
Abstract translation: 本发明提供了减少受试者的活细胞中的炎症的方法。 该方法增加了活细胞内硫辛酸合酶的水平，从而导致炎症的减轻。 设想了各种实施例和变体，其中的一些在本文件结尾处以权利要求格式阐述。 在权利要求格式中如此示例的方面，实施例和变体不应被理解为限制本发明。
-
公开(公告)号：WO2011048112A1
公开(公告)日：2011-04-28
申请号：PCT/EP2010/065747
申请日：2010-10-19
Applicant: NOVARTIS AG , BEBERNITZ, Gregory, Raymond , BOCK, Mark, G. , REDDY, Dumbala Srinivas , HAJARE, Atul Kashinath , VYAVAHARE, Vinod , BHOSALE, Sandeep Bhausaheb , KURHADE, Suresh Eknath , SALUNKHE, Videsh , SHAIKH, Nadim, S. , BHUNIYA, Debnath , PALLE, P., Venkata , FENG, Lili , LIANG, Jessica
Inventor： BEBERNITZ, Gregory, Raymond , BOCK, Mark, G. , REDDY, Dumbala Srinivas , HAJARE, Atul Kashinath , VYAVAHARE, Vinod , BHOSALE, Sandeep Bhausaheb , KURHADE, Suresh Eknath , SALUNKHE, Videsh , SHAIKH, Nadim, S. , BHUNIYA, Debnath , PALLE, P., Venkata , FENG, Lili , LIANG, Jessica
IPC: C07D405/10 , C07D407/10 , C07D413/10 , A61K31/70 , A61P3/10
CPC classification number: A61K31/7052 , A61K31/7048 , A61K31/706 , C07D405/10 , C07D407/10 , C07D413/10 , C07H7/04
Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
Abstract translation: 本发明涉及由式（I）表示的化合物：其中变量如上文所定义，其可用于治疗D-葡萄糖共转运蛋白（SGLT）介导的疾病和病症，例如， 糖尿病。 本发明还提供了治疗这些疾病和病症以及组合物等的治疗方法。
-
公开(公告)号：WO2010031820A1
公开(公告)日：2010-03-25
申请号：PCT/EP2009/062069
申请日：2009-09-17
Applicant: NOVARTIS AG , PALLE, P., Venkata , BHUNIYA, Debnath , REDDY, Dumbala Srinivas , KURHADE, Suresh Eknath
IPC: A61K31/351 , C07D309/10 , A61P3/10
CPC classification number: C07D309/10 , C07D405/06
Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.
Abstract translation: 本发明涉及式（I）的化合物及其药学上可接受的盐，用于治疗代谢紊乱的制剂和用途。
-
Patent Agency Ranking
公开(公告)号：WO2010031813A1
公开(公告)日：2010-03-25
申请号：PCT/EP2009/062054
申请日：2009-09-17
Applicant: NOVARTIS AG , BHUNIYA, Debnath , KURHADE, Suresh Eknath , PALLE, P., Venkata , REDDY, Dumbala Srinivas
IPC: C07D309/10 , A61K31/351 , A61P3/10
CPC classification number: C07D309/10
Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of, interalia, metabolic disorders.
Abstract translation: 本发明涉及式（I）的化合物及其药学上可接受的盐，用于治疗代谢紊乱的制剂和用途。
-
7.发明申请METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION, OBESITY AND RELATED METABOLIC DISORDERS 审中-公开治疗炎症，肥胖和相关代谢障碍的方法和组合物
公开(公告)号：WO2008036966A2
公开(公告)日：2008-03-27
申请号：PCT/US2007/079284
申请日：2007-09-24
Applicant: Reddy US Therapeutics, Inc. , PADMALAYAM, Indira , BHUNIYA, Debnath , REDDY, Dumbala Srinivas , KHANNA, Ish, K. , SAXENA, Uday , PILLARISETTI, Sivaram
Inventor： PADMALAYAM, Indira , BHUNIYA, Debnath , REDDY, Dumbala Srinivas , KHANNA, Ish, K. , SAXENA, Uday , PILLARISETTI, Sivaram
IPC: A61K31/385
CPC classification number: A61K31/385 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158
Abstract: This invention provides a method of reducing inflammation in a living cell of a subject. This method increases the level of lipoic acid synthase within the living cell thereby causing the reduction of the inflammation. Various embodiments and variants are contemplated, some of which are set forth in claim format at the end of this document. The aspects, embodiments, and variants so exemplified in the claims format should not be understood as limiting the invention.
Abstract translation: 本发明提供减少受试者活细胞中的炎症的方法。 该方法提高了活细胞内硫辛酸合成酶的水平，从而导致炎症的减少。 考虑了各种实施例和变型，其中一些在本文件结尾处以权利要求格式阐述。 在权利要求书格式中如此举例说明的方面，实施例和变型不应被理解为限制本发明。
-
公开(公告)号：WO2011048148A2
公开(公告)日：2011-04-28
申请号：PCT/EP2010/065802
申请日：2010-10-20
Applicant: NOVARTIS AG , BEBERNITZ, Gregory Raymond , BOCK, Mark G. , BHUNIYA, Debnath , DATRANGE, Laxmikant , KURHADE, Suresh Eknath , PALLE, P. Venkata , REDDY, Dumbala Srinivas
Inventor： BEBERNITZ, Gregory Raymond , BOCK, Mark G. , BHUNIYA, Debnath , DATRANGE, Laxmikant , KURHADE, Suresh Eknath , PALLE, P. Venkata , REDDY, Dumbala Srinivas
IPC: C07H15/203 , C07H15/26 , C07H17/00 , C07H19/04 , C07D309/10 , C07D309/30 , C07D405/10 , C07D407/10 , C07D407/12 , C07D409/04 , C07D409/10 , C07D409/12 , C07D413/10 , C07D493/10 , C07D498/04 , C07D491/107 , A61K31/7042 , A61K31/7034 , A61K31/7056 , A61K31/351 , A61P3/10
CPC classification number: C07H17/00 , A61K31/351 , A61K31/7034 , A61K31/7042 , A61K31/7056 , A61K38/28 , A61K45/06 , C07D309/10 , C07D309/30 , C07D405/10 , C07D407/10 , C07D407/12 , C07D409/04 , C07D409/10 , C07D409/12 , C07D413/10 , C07D491/107 , C07D493/10 , C07D498/04 , C07H15/203 , C07H15/26 , C07H19/04 , A61K2300/00
Abstract: This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
Abstract translation: 本发明涉及由式（I）表示的化合物，其中变量如上文所定义，其可用于治疗由D-葡萄糖共转运蛋白（SGLT）介导的疾病和病症，例如， 糖尿病。 本发明还提供了治疗这些疾病和病症以及组合物等的治疗方法。
-
公开(公告)号：WO2010128152A1
公开(公告)日：2010-11-11
申请号：PCT/EP2010/056286
申请日：2010-05-07
Applicant: NOVARTIS AG , BEBERNITZ, Gregory Raymond , BHOSALE, Sandeep Bhausaheb , BHUNIYA, Debnath , HAJARE, Atul Kashinath , MENGAWADE, Tanaji , MUKHOPADHYAY, Partha P. , PALLE, P. Venkata , REDDY, Dumbala Srinivas
Inventor： BEBERNITZ, Gregory Raymond , BHOSALE, Sandeep Bhausaheb , BHUNIYA, Debnath , HAJARE, Atul Kashinath , MENGAWADE, Tanaji , MUKHOPADHYAY, Partha P. , PALLE, P. Venkata , REDDY, Dumbala Srinivas
IPC: C07H7/06 , C07H7/04 , A61K31/70 , A61K31/7048 , A61K31/7052 , A61K31/7056 , A61K31/706 , A61P3/10
CPC classification number: C07H7/06 , A61K31/70 , A61K31/7048 , A61K31/7052 , A61K31/7056 , A61K31/706 , C07D491/04 , C07D493/04 , C07D498/04 , C07H7/04
Abstract: The present invention provides compounds of Formula (IA) wherein A is selected from Formula (II) which have an inhibitory effect on the sodium dependent glucose transporter SGLT and their use in the treatment of diabetes.
Abstract translation: 本发明提供式（IA）化合物，其中A选自式（II），其对钠依赖性葡萄糖转运蛋白SGLT具有抑制作用及其在治疗糖尿病中的用途。
-
公开(公告)号：WO2008036967A3
公开(公告)日：2008-03-27
申请号：PCT/US2007/079286
申请日：2007-09-24
Applicant: Reddy US Therapeutics, Inc. , REDDY, Dumbala Srinivas , PADMALAYAM, Indira , BHUNIYA, Debnath , PILLARISETTI, Sivaram , CHAKRABARTI, Ranjan
Inventor： REDDY, Dumbala Srinivas , PADMALAYAM, Indira , BHUNIYA, Debnath , PILLARISETTI, Sivaram , CHAKRABARTI, Ranjan
IPC: C07D209/14 , C07D209/12 , A61K31/404
Abstract: This invention provides a compound of formula (I), which is a free species and/or a pharmaceutically-acceptable salt or a stereoisomer of the compound of formula (I). Another aspect of the present invention provides the compound of the formula (I) as a Lipoic acid synthase (LASY) inducer
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.017 seconds)
